Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study
- PMID: 33387477
- PMCID: PMC7869891
- DOI: 10.1016/S2352-3018(20)30268-X
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study
Abstract
Background: Dolutegravir has been widely available in Brazil since 2017. Following the signal that infants born to women with dolutegravir exposure at conception in Botswana had a higher risk of neural tube defects (NTDs), public health leaders initiated a national investigation to evaluate periconception dolutegravir exposure among all pregnant Brazilian women with HIV and its potential association with risk of NTDs, stillbirth, or miscarriage before 22 weeks (also called spontaneous abortion).
Methods: In this retrospective, observational, national, cohort study, we identified all women with pregnancies and possible dolutegravir exposure within 8 weeks of estimated date of conception between Jan 1, 2017, and May 31, 2018, and approximately 3:1 matched pregnant women exposed to efavirenz between Jan 1, 2015, and May 31, 2018, using the Brazilian antiretroviral therapy database. We did detailed chart reviews for identified women. The primary outcomes were NTD and a composite measure of NTD, stillbirth, or miscarriage. NTD incidences were calculated with 95% CI. The composite outcome was examined with logistic regression using propensity score matching weights to balance confounders.
Findings: Of 1427 included women, 382 were exposed to dolutegravir within 8 weeks of estimated date of conception. During pregnancy, 183 (48%) of 382 dolutegravir-exposed and 465 (44%) of 1045 efavirenz-exposed women received folic acid supplementation. There were 1452 birth outcomes. There were no NTDs in either dolutegravir-exposed (0, 95% CI 0-0·0010) or efavirenz-exposed groups (0, 95% CI 0-0·0036). There were 23 (6%) stillbirths or miscarriages in 384 dolutegravir-exposed fetuses and 28 (3%) in the 1068 efavirenz-exposed fetuses (p=0·0037). Logistic regression models did not consistently indicate an association between dolutegravir exposure and risk of stillbirths or miscarriages. After study closure, two confirmed NTD outcomes in fetuses with periconception dolutegravir exposure were reported to public health officials. An updated estimate of NTD incidence incorporating these cases and the estimated number of additional dolutegravir-exposed pregnancies between Jan 1, 2015 and Feb 28, 2019, is 0·0018 (95% CI 0·0005-0·0067).
Interpretation: Neither dolutegravir nor efavirenz exposure was associated with NTDs in our national cohort; incidence of NTDs is probably well under 1% in dolutegravir-exposed HIV-positive women but still slightly above HIV-uninfected women (0·06%) in Brazil.
Funding: The Brazilian Ministry of Health and the United States' National Institutes of Health.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7869891/bin/nihms-1664153-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7869891/bin/nihms-1664153-f0002.gif)
Similar articles
-
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7. Lancet. 2021. PMID: 33812487 Free PMC article. Clinical Trial.
-
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.EBioMedicine. 2021 Jan;63:103167. doi: 10.1016/j.ebiom.2020.103167. Epub 2020 Dec 18. EBioMedicine. 2021. PMID: 33341441 Free PMC article.
-
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.Ann Pharmacother. 2020 Dec;54(12):1252-1259. doi: 10.1177/1060028020933772. Epub 2020 Jun 9. Ann Pharmacother. 2020. PMID: 32517480 Review.
-
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.N Engl J Med. 2019 Aug 29;381(9):827-840. doi: 10.1056/NEJMoa1905230. Epub 2019 Jul 22. N Engl J Med. 2019. PMID: 31329379 Free PMC article.
-
Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.Ann Pharmacother. 2019 Aug;53(8):833-844. doi: 10.1177/1060028019830788. Epub 2019 Feb 10. Ann Pharmacother. 2019. PMID: 30739498 Review.
Cited by
-
Dolutegravir induces FOLR1 expression during brain organoid development.Front Mol Neurosci. 2024 May 17;17:1394058. doi: 10.3389/fnmol.2024.1394058. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38828282 Free PMC article.
-
Dolutegravir and Folic Acid Interaction during Neural System Development in Zebrafish Embryos.Int J Mol Sci. 2024 Apr 24;25(9):4640. doi: 10.3390/ijms25094640. Int J Mol Sci. 2024. PMID: 38731859 Free PMC article.
-
Antiretroviral Regimen and Pregnancy Outcomes of Women Living with HIV in a US Cohort.Infect Dis Clin Pract (Baltim Md). 2023 Nov;31(6):e1308. doi: 10.1097/IPC.0000000000001308. Epub 2023 Sep 25. Infect Dis Clin Pract (Baltim Md). 2023. PMID: 38213314
-
Metabolic implications and safety of dolutegravir use in pregnancy.Lancet HIV. 2023 Sep;10(9):e606-e616. doi: 10.1016/S2352-3018(23)00141-8. Epub 2023 Aug 4. Lancet HIV. 2023. PMID: 37549681 Review.
-
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study.Lancet HIV. 2023 Sep;10(9):e588-e596. doi: 10.1016/S2352-3018(23)00108-X. Epub 2023 Jul 25. Lancet HIV. 2023. PMID: 37506721
References
-
- Organization WH. Consolidated guidelines on the use of antiretroviral durgs for treating and preventing HIV infection: World Health Organization, 2016. - PubMed
-
- Federal Government of Brazil. Federal Law 9,313. Brasilia, Brazil; 1996. Available at http://www.planalto.gov.br/ccivil_03/leis/L9313.htm. Accessed June 19, 2020.
-
- Brazilian Ministry of Health. Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos, 2017. Brasilia, Brazil; 2017. Available at http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizestera.... Accessed June 19, 2020.
-
- Brazilian Ministry of Health. Relatório de Monitoramento Clínico Do HIV. Brasilia, Brazil; 2018. Available at http://www.aids.gov.br/pt-br/pub/2018/relatorio-de-monitoramento-clinico.... Accessed June 19, 2020.
-
- Brazilian Ministry of Health. Disponibilidade de dolutegravir 50mg Ofício-Circular N 003/2017-GAB/DDAHV/SVS/MS. Brasilia, Brazil; 2017. Available at http://azt.aids.gov.br/documentos/siclom_operacional/Of%C3%ADcio%20circu.... Accessed June 19, 2020.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical